Nexien BioPharma Past Earnings Performance
Past criteria checks 0/6
Nexien BioPharma has been growing earnings at an average annual rate of 46.2%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
46.2%
Earnings growth rate
49.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nexien BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 2 | 0 |
| 31 Mar 21 | 0 | -2 | 2 | 0 |
| 31 Dec 20 | 0 | -3 | 3 | 0 |
| 30 Sep 20 | 0 | -3 | 3 | 0 |
| 30 Jun 20 | 0 | -3 | 3 | 0 |
| 31 Mar 20 | 0 | -3 | 3 | 0 |
| 31 Dec 19 | 0 | -3 | 3 | 0 |
| 30 Sep 19 | 0 | -4 | 4 | 0 |
| 30 Jun 19 | 0 | -4 | 4 | 0 |
| 31 Mar 19 | 0 | -4 | 3 | 0 |
| 31 Dec 18 | 0 | -3 | 3 | 0 |
| 30 Sep 18 | 0 | -2 | 2 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
| 31 Mar 18 | 0 | -2 | 2 | 0 |
Quality Earnings: NXEN is currently unprofitable.
Growing Profit Margin: NXEN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NXEN is unprofitable, but has reduced losses over the past 5 years at a rate of 46.2% per year.
Accelerating Growth: Unable to compare NXEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: NXEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.